https://orcid.org/0000-0001-7482-4596
References
- Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369(9573):1627–1640. doi: 10.1016/S0140-6736(07)60750-8.
- Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769–2778. doi: 10.1016/S0140-6736(17)32448-0.
- Mohammed Vashist N, Samaan M, Mosli MH, et al. Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis. Cochrane Database Syst Rev. 2018;1(1):CD011450.
- Rowan CR, Cullen G, Mulcahy HE, et al. Dublın [degree of ulcerative colitis burden of luminal ınflammation] score, a simple method to quantify ınflammatory burden in ulcerative colitis. J Crohns Colitis. 2019;13(11):1365–1371. doi: 10.1093/ecco-jcc/jjz067.
- Lalosevic MS, Milutinovic AS, Zaric VM, et al. Intestinal ultrasonography as a tool for monitoring disease activity in patients with ulcerative colitis. Int J Clin Pract. 2022;2022:1–6.
- Lin CF, Zhang LP, Xie SY, et al. Pan-Immune-ınflammation value: a new prognostic ındex in operative breast. Front Oncol. 2022;12:830138. doi: 10.3389/fonc.2022.830138.
- Chen JH, Zhai ET, Yuan YJ, et al. Systemic immune-inflammation index for predicting prognosis of colorectal cancer. World J Gastroenterol. 2017;23(34):6261–6272. doi: 10.3748/wjg.v23.i34.6261.
- Yan J, Deng F, Tan Y, et al. Systemic immune-inflammation index as a potential biomarker to monitor ulcerative colitis. Curr Med Res Opin. 2023;39(10):1321–1328. doi: 10.1080/03007995.2023.2257599.
- Xie Y, Zhuang T, Ping Y, et al. Elevated systemic immune inflammation index level is associated with disease activity in ulcerative colitis patients. Clin Chim Acta. 2021;517:122–126. doi: 10.1016/j.cca.2021.02.016.
- Zhang M-H, Wang H, Wang H-G, et al. Effective immune-inflammation index for ulcerative colitis and activity assessments. World J Clin Cases. 2021;9(2):334–343. doi: 10.12998/wjcc.v9.i2.334.
- Pakoz ZB, Ustaoglu M, Vatansever S, et al. Serum ımmune- ınflammation index assessment in the patients with ulcerative colitis. Gastroenterol Res Pract. 2022;2022:9987214–9987215. doi: 10.1155/2022/9987214.
- Karadağ I, Karakaya S, Yılmaz ME, et al. The potential prognostic novel markers PIV and PILE score to predict survival outcomes at hepatocellular cancer. Eur Rev Med Pharmacol Sci. 2022;26(20):7679–7686.
- Ligorio F, Fucà G, Zattarin E, et al. The pan-ımmune-ınflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab. Cancers. 2021;13(8):1964. doi: 10.3390/cancers13081964.
- Öksüm Solak E, Baran Ketencioglu B, Cinar SL, et al. The role of new inflammatory markers in determining disease activation and severity in patients with hidradenitis suppurativa. Int J Dermatol. 2023;62(8):1076–1081. doi: 10.1111/ijd.16744.
- Tutan D, Doğan AG. Pan-ımmune-inflammation ındex as a biomarker for rheumatoid arthritis progression and diagnosis. Cureus. 2023;15(10):e46609. doi: 10.7759/cureus.46609.
- Lindsay JO, Picker N, Kromer D, et al. The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom. Curr Med Res Opin. 2023;39(5):681–689. doi: 10.1080/03007995.2023.2194782.
- Chetwood JD, Gupta S, Subramaniam K, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis – national extended follow-up and a review of the literature. Expert Opin Drug Saf. 2023:1–8. doi: 10.1080/14740338.2023.2278686.